

**Remarks:**

**A. Status of the Claims**

Claims 1-34 were pending when the Restriction Requirement dated March 3, 2006, was mailed to Applicants. Claims 10-34 have been canceled, and no claims have been added.

**B. Applicants Elect Group I**

The Restriction Requirement requests restriction between one of the following two groups:

Group I: Claims 1-9, drawn to a pharmaceutical dosage form; and

Group II: Claims 10-34, drawn to a method of improving patient compliance or diminishing the incidence of erroneous ingestion by providing indicia to distinguish dosage forms.

In response to the Restriction Requirement, Applicants elect Group I, claims 1-9, for further prosecution. Applicants note that a divisional application is being filed today directed to claims 10-34.

**C. Conclusion**

Applicants believe that this is a full and complete response to the Restriction Requirement dated March 3, 2006. It is believed that no fee is due for filing this Response to the Restriction Requirement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, consider this paragraph such a request and authorization to withdraw the appropriate fee from Fulbright & Jaworski Deposit Account No. 50-1212/GOUD:031US.

Should the Examiner have any questions, comments, or suggestions relating to this case,  
the Examiner is invited to contact the undersigned Applicants' representative at (512) 536-3020.

Respectfully submitted,



Michael R. Krawzsenek  
Reg. No. 51,898  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3020  
(512) 536-4598 (facsimile)

Date: March 20, 2006